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A B S T R A C T
Background: The burden of cardiovascular disease is increasing, yet it remains difﬁcult to focus
preventive strategies on populations at highest absolute and relative risks. We compared absolute and
relative cardiovascular event counts, plus time to ﬁrst event, among patients undergoing myocardial
perfusion scintigraphy (MPS).
Methods and results: Our database was queried to identify subjects without myocardial necrosis or
recent revascularization, focusing on cardiac death (CD) or myocardial infarction (MI). A total of 13,254
patients were included, 5436 (41%) without, and 7818 (59%) with ischemia. After 32  21 months,
subjects without ischemia, compared to those with ischemia, had lower absolute (16 vs 75 events, 18% vs
82%, p < 0.001) and relative (0.3% vs 1.3%, p < 0.001) risk of CD. Similar ﬁndings were obtained for MI (52 vs
81 events, 39% vs 61%, p < 0.001, with corresponding rates of 1.0% vs 1.4%, p < 0.001, respectively). Medical
therapy appeared associated with fewer outcomes in those without ischemia, with the opposite occurring for
subjects with ischemia (p < 0.001). Median times to event ranged between 13 and 25 months in patients
without ischemia vs 2 and 14 months in those with ischemia (p < 0.001 for all comparisons). Multivariable-
adjusted and propensity matched analyses conﬁrmed the independent prognostic role of myocardial
ischemia and, apparently, revascularization.
Conclusion: Most fatal and non-fatal cardiac events appear to occur in patients with evidence of
myocardial ischemia at MPS, especially those with moderate or severe ischemia not receiving
revascularization during follow-up.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The global burden of cardiovascular disease continues to
increase, despite substantial improvements in prognostic, diagnos-
tic, and management strategies in several countries [1]. Accordingly,
it is paramount to improve and maximize preventive means of* Corresponding author at: Servizio di Cardiologia Nucleare, Clinica Madonna
della Fiducia Via Cesare Correnti 6, 00179 Rome, Italy. Tel.: +39 0678359705;
fax: +39 0678462970.
E-mail addresses: francesco.nudi@gmail.com, francesco.nudi@etisan.eu (F. Nudi).
http://dx.doi.org/10.1016/j.jjcc.2014.11.007
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsproven efﬁcacy and safety in speciﬁc subpopulations. There is
however uncertainty on which population subset should be targeted
most aggressively [2–4]. This issue is further complicated by
discrepancies between clinical and pathologic series appraising the
association between coronary artery disease severity and clinical
events. Speciﬁcally, most clinical series have reported that the
majority of cardiovascular events occur, in absolute terms, in
patients without severe coronary artery disease [5,6]. Conversely,
pathologic series have typically concluded that most fatal cardio-
vascular events occur in subjects with severe coronary lesions [5,7].
Myocardial perfusion scintigraphy (MPS) offers an accurate and
robust tool to appraise the ischemic (i.e. clinical) impact of reserved.
F. Nudi et al. / Journal of Cardiology 66 (2015) 125–129126suspected coronary artery disease [8,9]. Accordingly, we hypothe-
sized that patient stratiﬁcation according to MPS results could
clarify the association between ischemic burden and event rates in
patients with or at risk for coronary artery disease. We thus
analyzed our institutional database to precisely quantify time to
and risk of cardiac events after MPS.
Methods
This was a retrospective observational study exploiting
prospectively collected data entered into a dedicated administra-
tive database (OPCCardioPro, ETISAN, Rome, Italy) [9]. All patients
provided written informed consent for imaging test and data
collection and the competent institutional authority was notiﬁed.
Patients undergoing MPS for the diagnostic or prognostic work-
up of coronary artery disease since April 2004 at our center were
identiﬁed, excluding those aged <18 years, ineligible for 1-year
clinical follow-up, having a history of coronary revascularization
within the last 6 months before MPS, or evidence of myocardial
necrosis at MPS. The test and imaging protocol has been described
in detail elsewhere [9]. Brieﬂy, semiquantitative interpretation of
stress/rest images was performed based on the above 7-region
model by consensus of 2 experienced observers using both visual
assessment of the color-coded tomographic images for the 3 axes
and the standard deviation (SD) polar map of detectable tracer
uptake, ﬁnally obtaining for each region a 5-point scoring system
(0 – normal uptake; 1 – minimally reduced uptake; 2 – mildly
reduced uptake; 3 – moderately reduced uptake; and 4 – severely
reduced or absent uptake). This score directly yielded the 5 classes
of maximal ischemia score (MIS; 0 – no ischemia; 1 – minimal
ischemia; 2 – mild ischemia; 3 – moderate ischemia; 4 – severe
ischemia), with the ﬁnal MIS strictly depending on the worst
region of perfusion.
Clinical follow-up was systematically collected after the index
MPS, by direct patient visit or telephone contact. In case an adverse
event was elicited, hard copies of the source documents (e.g.
hospitalization records) were retrieved to enable event adjudica-
tion and minimize information bias. Outcomes of interest were the
long-term rates of cardiac death (CD), myocardial infarction (MI),
revascularization, or their composite.
Continuous variables are reported as mean  standard devia-
tion. Categorical variables are reported as n (%), with 95% conﬁdence
intervals built according to the adjusted Wald method. Bivariate
analyses were performed using ANOVA for continuous variables, chi-
squared test for categorical variables, and Kaplan–Meier method for
survival analysis, whereas times to event were computed with
bootstrapped 95% conﬁdence intervals of median values (based on
1000 samples), and compared with the log-rank test. Multivariable
adjusted analysis was performed with Cox proportional hazard
analysis entering as covariates all variables associated at bivariate
p < 0.10 with MIS [reporting results as hazard ratios (HR) with 95%
conﬁdence intervals], with backward selection. Propensity scores
were also generated to appraise the prognostic impact of revasculari-
zation vs medical therapy with a non-parsimonious logistic regres-
sion analysis, and then used to identify propensity matched pairs (1:1
ratio) using a 0.001 caliper [10]. Signiﬁcance was set at the 2-tailed
0.05 level, and p-values unadjusted for multiplicity are reported
throughout. Computations were performed with SPSS 20 (IBM,
Armonk, NY, USA) and Stata 13 (StataCorp, College Station, TX, USA).
Results
A total of 13,254 patients were included, 5436 (41%) without
ischemia, 2095 (16%) with minimal ischemia, 3096 (23%) with mild
ischemia, 1782 (13%) with moderate ischemia, and 845 (6%) with
severe ischemia. Several differences were found, as expected, inbaseline and procedural features when comparing such groups
(Online Tables 1 and 2).
After 32  21 months of follow-up, patients without ischemia
were at signiﬁcantly lower absolute and relative risks of CD than
subjects with ischemia, with corresponding differences in warranty
periods (Table 1). Speciﬁcally, CD occurred in 16 vs 75, thus
representing 18% vs 82% of all such events, with corresponding rates
of 0.3% vs 1.3% (p < 0.001). Similar ﬁndings were obtained for MI, as
patients without ischemia had lower absolute and relative risks of
this event in comparison to subjects with ischemia, despite the fact
that in absolute terms several still occurred in these patients: 52 vs
81, representing 39% vs 61% of all MIs, with corresponding rates of
1.0% vs 1.4% (p < 0.001).
Notably, in patients without ischemia, medical therapy
appeared associated with a signiﬁcantly lower risk of MI, as well
as CD or their composite, than revascularization (respectively 1.0%
vs 6.3%, p < 0.001, 0.3% vs 1.0%, p < 0.001, and 1.3% vs 7.3%,
p < 0.001). Conversely, revascularization was apparently associat-
ed with markedly lower risks of MI, CD, or their composite in
comparison to medical therapy in patients with moderate or
severe ischemia.
Similar results to those obtained for CD or MI occurred when
focusing on revascularizations or the composite of CD or MI, or
revascularization (Table 2). Warranty periods, estimated from
median time to events, were also signiﬁcantly different
according to the degree of ischemia. Speciﬁcally, CD occurred
a median of 21 (95% conﬁdence interval 12–24) months after the
index MPS among subjects without ischemia vs 10 (7–12)
months among those with ischemia. Corresponding ﬁgures for
MI, revascularization, and their composite, were, respectively,
25 (21–29) vs 14 (8–22), 13 (11–17) vs 2 (2–2), and 14 (12–16)
vs 2 (2–2).
Several sensitivity analyses were performed, including those
excluding events occurring less than 3 months after MPS, as well as
those based on the inclusion of all patients and normalizing event
burdens according to crude event rates stemming from the cohort
of subjects not receiving revascularization during follow-up,
further conﬁrming the above ﬁndings (Online Tables 3–5). Notably,
analysis stratiﬁed according to the ﬁndings of coronary angiogra-
phy (any catheterization, 1 – vessel disease, 2 – vessel disease, and
3 – vessel disease) conﬁrmed our ﬁndings in terms of statistical
magnitude and direction. We also performed multivariable-
adjusted Cox proportional hazard analysis to identify independent
predictors of CD or MI (Online Table 6), conﬁrming that MIS was a
signiﬁcant independent predictor [HR = 1.23 (1.07–1.41,
p = 0.003)], together with age [HR = 1.05 (1.03–1.07), p < 0.001],
body mass index [HR = 1.04 (1.00–1.07), p = 0.048], maximum ST-
segment deviation [HR = 1.22 (1.01–1.48), p = 0.043], ejection
fraction [HR = 0.97 (0.95–0.98), p < 0.001], and revascularization
as ﬁrst follow-up event [HR = 0.65 (0.44–0.96)]. Risk-adjusted
estimates of the prognostic impact of myocardial ischemia on CD
or MI, as well as on the other endpoints, were also similar to
unadjusted estimates, with the majority of CD or MI events
occurring in patients with objective evidence of myocardial
ischemia.
Propensity score matched pairs were also obtained to compare
revascularization vs medical therapy, aiming at minimizing the
role of confounders. Analysis based on such propensity matched
pairs showed that revascularization was apparently associated
with a signiﬁcantly lower risk of CD or MI than medical therapy in
patients with objective evidence of myocardial ischemia [HR for CD
or MI = 0.35 (0.16–0.74); HR for MI = 0.21 (0.06–0.75)], as well as a
trend toward fewer CDs [HR = 0.50 (0.19–1.33)]. Finally, analyses
limited to patients with adverse events showed that MIS, ejection
fraction, and ST-segment deviation were independent predictors of
shorter time to event.
Table 1
Unadjusted analysis for absolute counts, relative counts, and time to events for cardiac death (CD) or myocardial infarction (MI) according to maximal ischemia score (MIS),
excluding patients undergoing revascularization as ﬁrst event during follow-up.a
Event Statistics Total
(N = 11,235)
No ischemia
(N = 5340)
Any myocardial ischemia p-value
Subtotal
(N = 5895)
Minimal
(N = 2003)
Mild
(N = 2601)
Moderate
(N = 964)
Severe
(N = 327)
CD Absolute count 91 16 75 6 26 20 23 <0.001
% Relative to
absolute counts
100% 17.6%
(11.0–26.8%)
82.4%
(73.2–89.0%)
6.6%
(2.8–13.9%)
28.6%
(20.3–38.6%)
22.0%
(14.6–31.6%)
25.3%
(17.4–35.1%)
% Relative to MIS 0.8%
(0.7–1.0%)
0.3%
(0.2–0.5%)
1.3%
(1.0–1.6%)
0.3%
(0.1–0.7%)
1.0%
(0.7–1.5%)
2.1%
(1.3–3.2%)
7.0
(4.7–10.4%)
Time to event
(months)
19
(15–22)
21
(12–24)
10
(7–12)
13
(6–19)
10
(7–12)
10
(5–14)
7
(5–13)
<0.001
Normalized
absolute countb
118 16 102 6 31 37 59 <0.001
Normalized %
relative to
absolute countsb
100% 13.6%
(8.4–21.0%)
86.4%
(79.0–91.6%)
5.1%
(2.1–10.9%)
26.3%
(19.1–34.9%)
31.3%
(23.7–40.2%)
50.0%
(41.1–58.9%)
MI Absolute count 133 52 81 21 25 25 10 <0.001
% Relative to
absolute counts
100% 39.1%
(31.2–47.6%)
60.9%
(52.4–68.8%)
15.8%
(10.5–23.0%)
18.8%
(13.0–26.3%)
18.8%
(13.0–26.3%)
7.5%
(4.0–13.4%)
% Relative to MIS 1.2%
(1.0–1.4%)
1.0%
(0.7–1.3%)
1.4%
(1.1–1.7%)
1.0%
(0.7–1.6%)
1.0%
(0.7–1.4%)
2.6%
(1.8–3.8%)
3.1%
(1.6–5.6%)
Time to event
(months)
18
(13–22)
25
(20–28)
13
(8–18)
21
(15–30)
7
(3–22)
10
(3–19)
12
(1–31)
0.023
Normalized
absolute countb
164 54 110 21 31 46 26 <0.001
Normalized %
relative to
absolute countsb
100% 32.9%
(26.2–40.5%)
67.1%
(59.6–73.8%)
12.8%
(8.5–18.9%)
18.9%
(13.6–25.6%)
28.1%
(21.7–35.4%)
15.9%
(11.0–22.3%)
CD or MI Absolute count 224 68 156 27 51 45 33 <0.001
% Relative to
absolute counts
100% 30.4%
(24.7–36.7%)
69.6%
(63.3–75.3%)
12.1%
(8.4–17.0%)
22.8%
(17.7–28.7%)
20.1%
(15.3–25.8%)
14.7%
(10.7–20.0%)
% Relative to MIS 2.0%
(1.8–2.3%)
1.3%
(1.0–1.6%)
2.6%
(2.3–3.1%)
1.3%
(0.9–2.0%)
2.0%
(1.5–2.6%)
4.7%
(3.5–6.2%)
10.1%
(7.2–13.9%)
Time to event
(months)
14
(12–16)
22
(17–27)
11
(9–14)
17
(13–23)
9
(7–13)
10
(5–14)
10
(5–12)
<0.001
Normalized
absolute countb
274 71 258 27 62 84 85 <0.001
Normalized %
relative to
absolute countsb
100% 21.6%
(21.1–31.4%)
78.4%
(90.7–96.4%)
8.2%
(6.8–14.0%)
18.8%
(18.1–28.0%)
25.5%
(25.5–36.4%)
25.8%
(25.8–36.7%)
a Dichotomous variables are reported as point estimates (95% conﬁdence interval according to the adjusted Wald method), and times to event are described as median
with 95% bootstrapped conﬁdence intervals (1000 samples), compared with log-rank test.
b According to distribution of patients at risk reported in Online supplement.
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Efforts aiming at minimizing the burden of cardiovascular
disease have always been fraught by the difﬁculty in maximizing
effectiveness while minimizing costs and hazards [5]. Accordingly,
the identiﬁcation of people at higher risk of adverse events has
been the constant focus of patients, cardiovascular specialists, and
policy makers alike [11,12]. In simplistic terms, there are two
alternative perspectives pertinent to the concept of risk and
burden. Speciﬁcally, risk may be dramatically higher in a subset of
the population. Yet, if such a subset is tiny, the overall burden of
disease attributable to this group of patients may be correspond-
ingly small. Conversely, patients with a relatively low risk of
adverse events may impact dramatically on burden estimates if
they represent the vast majority of the overall population.
Two main hypotheses have prevailed so far on the estimate of
coronary artery disease burden in developed countries [5,13]. The
ﬁrst paradigm, largely based on clinical series exploiting coronary
angiography, states that most adverse cardiac events occur in
patients without severe coronary lesions, and thus these people
should be the main focus of preventive strategies [6,14,15]. The
opposing paradigm, based largely on pathologic series, purports
that most adverse cardiac events occur in patients with severe
coronary artery disease, and thus they should be the main target
of healthcare interventions aimed at reducing the burden ofcardiovascular disease [7,16,17]. Attempts at reconciling these
discrepancies have been to date limited in success. Our work
provides interesting results suggesting that adverse events occur
more frequently, in both relative and absolute terms, among
patients with evidence of myocardial ischemia and supports
previous ﬁndings by Hachamovitch et al. [4]. Furthermore, our
study has several distinct strengths, including the large sample
size, inclusion of patients more reﬂective of current cardiovascular
treatment patterns, focus on several different outcomes, compu-
tation of normalized absolute and counts, assessment of warranty
periods, and extensive risk-adjustment with standard Cox
proportional hazard analysis and propensity score matching.
Notably, the fact that adverse events occur more commonly in
patients with ischemia, in absolute and relative terms, holds true
for all cardiac events, both fatal and non-fatal, but is especially
valid for CD. Similar ﬁndings were obtained for revascularization
and the composite of CD, MI, and revascularization, or when
focusing on counts relative to patients at risk or time to events.
Analysis focusing on MI shows a similarly important but less
progressive impact of severity of ischemia. At ﬁrst, comparison of
patients with vs without ischemia conﬁrms that most MIs occurred
in the ﬁrst group. However, comparison of event counts relative to
patients at risk suggests a less dramatic (irrespective of statistical
signiﬁcance) increase in risk, going from 1.0% in those without
ischemia to 3.1% in those with ischemia. This does not translate
Table 2
Unadjusted analysis for absolute counts, relative counts, and time to events for coronary revascularization and the composite of cardiac death (CD), myocardial infarction
(MI), or revascularization according to maximal ischemia score (MIS).a
Event Statistics Total
(N = 13,254)
No ischemia
(N = 5436)
Any myocardial ischemia p-value
Subtotal
(N = 7818)
Minimal
(N = 2095)
Mild
(N = 3096)
Moderate
(N = 1782)
Severe
(N = 845)
Revascularization Absolute count 2498 256 2242 163 635 895 549 <0.001
% Relative to
absolute counts
100% 10.2%
(9.1–11.5%)
89.8%
(88.5–90.9%)
6.5%
(5.6–7.6%)
25.4%
(23.8–27.2%)
35.8%
(34.0–37.7%)
22.0%
(20.4–23.6%)
% Relative to MIS 18.8%
(18.2–19.5%)
4.7%
(4.2–5.3%)
28.7%
(27.7–29.7%)
7.8%
(6.7–9.0%)
20.5%
(19.1–22.0%)
50.2%
(47.9–52.5%)
65.0%
(61.7–68.1%)
Time to event
(months)
2
(2–3)
13
(11–17)
2
(2–2)
9
(7–11)
3
(3–4)
2
(2–2)
1
(1–1)
CD, MI, or
revascularizaton
Absolute count 2603 279 2324 171 661 919 573 <0.001
% Relative to
absolute counts
100% 10.7%
(9.6–12.0%)
89.3%
(88.0–90.4%)
6.6%
(5.7–7.6%)
25.4%
(23.8–27.1%)
35.3%
(33.5–37.2%)
22.0%
(20.5–23.7%)
% Relative to MIS 19.6%
(19.0–20.3%)
5.1%
(4.6–5.8%)
29.7%
(28.7–30.8%)
8.2%
(7.1–9.4%)
21.4%
(19.9–22.8%)
51.6%
(49.3–53.9%)
67.8%
(64.6–70.9%)
Time to event
(months)
3 (2–3) 14 (12–16) 2 (2–2) 9 (6–11) 3 (3–4) 2 (2–2) 1 (1–2) <0.001
Revascularization
occurring 3
months after MPS
Absolute count 1239 232 1007 137 373 337 160 <0.001
% Relative to
absolute counts
100% 18.7%
(16.5–20.9%)
81.3%
(79.1–83.4%)
11.1%
(9.4–12.8%)
30.1%
(27.6–32.7%)
27.2%
(24.7–29.7%)
12.9%
(11.0–14.8%)
% Relative to MIS 9.3%
(8.8–9.8%)
4.3%
(3.8–4.8%)
12.9%
(12.1–13.6%)
6.5%
(5.4–7.6%)
12.0%
(10.9–13.1%)
18.9%
(17.1–20.7%)
18.9%
(16.3–21.5%)
Time to event
(months)
8
(8–9)
17
(14–20)
7
(6–7)
11
(9–16)
8
(7–9)
5
(5–6)
5
(3–6)
<0.001
CD, MI, or revascularization
occurring 3 months
after MPS
Absolute count 1323 255 1.068 144 392 355 177 <0.001
% Relative to
absolute counts
100% 19.3%
(17.2–21.4%)
80.7%
(78.6–82.6%)
10.9%
(9.2–12.6%)
29.6%
(27.1–32.1%)
26.8%
(24.4–29.2%)
13.4%
(11.6–15.2%)
% Relative to MIS 10.0%
(9.4–10.5%)
4.7%
(4.1–5.3%)
13.7%
(12.9–14.4%)
6.9%
(5.8–8.0%)
12.7%
(11.5–13.9%)
19.9%
(18.0–21.8%)
20.9%
(18.2–23.6%)
Time to event
(months)
8
(8–9)
16
(13–20)
7
(6–7)
11
(9–14)
8
(7–9)
5
(5–6)
5
(5–6)
<0.001
MPS, myocardial perfusion scintigraphy.
a Dichotomous variables are reported as point estimate (95% conﬁdence interval according to the adjusted Wald method), and times to event are described as median
with 95% bootstrapped conﬁdence intervals (1000 samples), compared with log-rank test.
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aggressive revascularization strategy, especially in subjects
without ischemia, as we can show, in keeping with others [4]
that revascularization of non-ischemic coronary artery disease is
associated with worse outcomes. Moreover, our work was not
based on randomization and thus data on patients receiving
revascularization cannot be considered a deﬁnitive scientiﬁc proof
of its clinical validity in this setting.
Nonetheless, these ﬁndings have several implications. First,
they may reconcile discrepancies in prior works [5–7,13–
17]. Indeed, clinical studies by deﬁnition were excluding fatal
cardiac events, and thus were usually focusing on non-fatal MIs.
Conversely, pathologic studies were, per se, limited to fatal cardiac
events, and thus were not truly representative of the overall
population of patients at risk [5,7,16,17]. Moreover, both types of
studies were limited by an anatomic approach at quantifying
coronary artery disease severity which disregards the prognos-
tically crucial role of myocardial ischemic burden. More pragmati-
cally, our work may also be useful in the risk stratiﬁcation of
individual patients and in decision-making at large, as well as in
supporting ongoing efforts at improving appropriate care, with
MPS appearing as a key component of appropriate decision-
making and management of patients with or at risk of coronary
artery disease.
This study has several drawbacks, including the retrospective,
observational, and single-center design, as well as the absence of
details on coronary anatomy on all included subjects. Accordingly,
prospective studies are required to conﬁrm or disprove our ﬁndings,
using standard or automated image analyses [18,19]. In addition,
our population is fraught by an inherent bias due to convenience
sampling, and thus may not be considered representative per seof the typical subjects in primary or secondary prevention settings,
but rather more truthfully corresponding to the stable patients
with or at risk of coronary artery disease undergoing MPS. While
our study builds upon several others in the ﬁeld [4,8,9,19,20], it
adds incremental scholarly value mainly because of three impor-
tant features. First, it represents a recent rather than remote
series of patients more similar to those physicians treat in current
clinical practice. Second, its sample size enables rather precise
event estimates and accurate as well as robust analyses. Third, and
most importantly, it exploits an altogether novel approach at
appraising the severity of myocardial ischemia at MPS, which was
originally described only recently [9]. Accordingly, it reinforces the
importance of looking at MPS as a diagnostic and prognostic
imaging modality with still signiﬁcant room for improvements and
reﬁnements.
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